Back to Search
EVAN SMALL, MD PHD
MD PHD
Emergency Medicine Physician
NPI: 1316202476IndividualAccepts Medicare
Specialties, Licenses & Credentials
Emergency Medicine PhysicianPrimary
Emergency Medicine
Code: 207P00000X
56725(MN)62573(WI)61617542(WA)
CMS Specialties
PrimaryEMERGENCY MEDICINE
Education
OTHER
Class of 2012
Research & Publications (20)
Do landscape factors affect brownfield carabid assemblages?
PMID 16274730·Sci Total Environ·2006
7-preclinical
Cul3-mediated Nrf2 ubiquitination and antioxidant response element (ARE) activation are dependent on the partial molar volume at position 151 of Keap1.
PMID 19489739·Biochem J·2009
8-other
Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer.
PMID 19380448·J Clin Oncol·2009
8-other
Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research.
PMID 19213669·Clin Genitourin Cancer·2009
8-other
A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102.
PMID 19168670·Ann Oncol·2009
3-trial
Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium.
PMID 19349545·J Clin Oncol·2009
8-other
Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF.
PMID 19147575·Cancer Res·2009
3-trial
Deficit in brain reward function and acute and protracted anxiety-like behavior after discontinuation of a chronic alcohol liquid diet in rats.
PMID 19048233·Psychopharmacology (Berl)·2009
7-preclinical
Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916.
PMID 19380444·J Clin Oncol·2009
3-trial
Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer.
PMID 19536890·Cancer·2009
3-trial
A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004.
PMID 18824434·Clin Genitourin Cancer·2008
3-trial
Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy.
PMID 18801509·J Urol·2008
3-trial
Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer.
PMID 18646045·Cancer·2008
3-trial
Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811.
PMID 18989865·Cancer·2008
3-trial
Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment.
PMID 18838703·J Clin Oncol·2008
1-meta
Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.
PMID 18936475·J Clin Oncol·2008
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 4 locations total
- Address
- 34515 9TH AVE S
FEDERAL WAY, WA 98003 - Phone
- (253) 838-9700
Quick Facts
- NPI
- 1316202476
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 3
- Locations
- 4
- Years in Practice
- 14
- Publications
- 20
Are you this provider?
Claim Your Profile